Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 20...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 30, 2024

The Gift of Woodworking: Rockler Announces Special Mother's Day and Father's Day Epoxy Classes for Parents and Kids • Henkel, Kraton and Dow Jointly Drive Sustainability in North American Consumer Goods Industry • Encore Media Brings KIDDO+ to Life with Immergo.tv's FAST Channel Playout Solution • Wisconsin Virtual Academy Earns Accreditation From Cognia • Latest Operation HOPE Research Shows Increasing Concern About the Economy and Impact of Inflation in the First Quarter of 2024 • KIA SPORTAGE PLUG-IN HYBRID WINS A 2024 BEST HYBRID AND ELECTRIC CARS AWARD FROM U.S. NEWS & WORLD REPORT • Bebefinn Expands with Its First Live Show, "Bebefinn LIVE - Bedtime Adventure" • Eastman and Lubrizol Collaborate to Enhance TPE Overmolding Adhesion With Sustainable Materials • Similarweb Appoints Susan Dunn as Chief Revenue Officer to Accelerate Revenue Growth • New Research Shows Remote Monitoring Is Effective to Improve Postpartum Assessment in Patients with Hypertensive Disorders of Pr • Kimberly-Clark Professional™ Announces Greenovation Awards for Sustainability Leadership and Waste Reduction • Sky High for Kids Receives $2 Million Pledge to Advance Pediatric Cancer Research • Markley Group Announces Green Power Partnership Program, Fueling the Company’s Commitment to 100 Percent Clean and Renewab • Climavision acquires Intersphere, bolstering leadership in AI-powered weather prediction • Research: Autonomous Trucks Can Reduce Emissions and Fight Climate Change • New Report Reveals that 9 out of 10 New Mothers Returning to Work Face At Least One Major Challenge That Threatens Career Succes • ASHA Shares New Resources on Developmental Milestones With Families This National Speech-Language-Hearing Month • Tetra Tech Wins $464 Million Multiple-Award Contract for Environmental Remediation Services • Wireside Communications® Kicks Off 2024 with Significant Growth, Expansion and Recognition • EXCLUSIVE: Tucker Carlson passionately defends parental rights on Moms For America Podcast

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

WATERTOWN, Mass. , April 17 /Businesswire/ - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”

Abstract Number: 02980

Poster Number: PO423

Day: April 27, 2024

Time: 12:00 p.m. CEST / 6:00 a.m. ET

Session Location: Poster Area

Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.